Table 1.
Clinicopathological characteristics of patients and univariate analysis for OS after SCR
| Cases | Deaths | Median OS (months) | UV a analysis ( P value) | |
|---|---|---|---|---|
|
Age at second surgery |
|
|
|
0.549 |
| ≤56 years |
38 |
15 |
60 |
|
| >56 years |
37 |
15 |
39 |
|
|
ECOG performance status at first surgery |
|
|
|
0.352 |
| 0 |
6 |
1 |
48.00 |
|
| 1 |
62 |
25 |
62.124 |
|
| 2 |
7 |
4 |
34.00 |
|
|
Stage at first surgery (FIGO 2009) |
|
|
|
0.760 |
| Stage I-II |
58 |
22 |
65.675 |
|
| Stage III-IV |
17 |
8 |
45.159 |
|
|
Pathological subtype |
|
|
|
0.180 |
| Endometrioid |
65 |
28 |
57.753 |
|
| Nonendometrioid |
10 |
2 |
52.10 |
|
|
Histological grade |
|
|
|
|
| I |
14 |
4 |
67.921 |
0.068 |
| II |
39 |
15 |
68.006 |
0.040* |
| III |
22 |
11 |
44.819 |
Reference |
|
Postoperative therapy after first surgery |
|
|
|
0.309 |
| Chemotherapy |
33 |
14 |
53.51 |
|
| Radiotherapy |
5 |
2 |
36 |
|
| CT+RT |
6 |
1 |
72 |
|
| Hormonal therapy |
4 |
1 |
114 |
|
| No |
27 |
12 |
36.196 |
|
|
Symptoms at recurrence |
|
|
|
0.723 |
| Nonsymptomatic |
30 |
13 |
54 |
|
| Symptomatic |
45 |
17 |
65 |
|
|
CA125 at recurrence |
|
|
|
0.108 |
| ≤ 35 U/ml |
25 |
7 |
69.650 |
|
| >35 U/ml |
35 |
18 |
35.733 |
|
| Not available |
15 |
5 |
77.548 |
|
|
Recurrence detection of nonsymptomatic |
|
|
|
0.134 |
| Imaging or CA-125 |
17 |
8 |
44.83 |
|
| Physical examination |
13 |
4 |
96 |
|
|
PFI |
|
|
|
0.032* |
| ≤18 months |
40 |
19 |
34.963 |
|
| >18 months |
35 |
11 |
76.078 |
|
|
Largest size of recurrence |
|
|
|
0.008* |
| ≤ 6 cm |
36 |
10 |
79.027 |
|
| > 6 cm |
39 |
20 |
35.918 |
|
|
Multiplicity of recurrence |
|
|
|
0.144 |
| Solitary |
35 |
12 |
73.219 |
|
| Multiple |
40 |
18 |
37.295 |
|
|
Site of recurrence |
|
|
|
0.056 |
| Pelvis
b
and/or introabdomonal |
63 |
23 |
66.186 |
|
| Retroperitoneal |
12 |
7 |
30.380 |
|
|
Ascites |
|
|
|
0.048* |
| None |
67 |
26 |
64.678 |
|
| Yes |
8 |
4 |
17.171 |
|
|
ECOG performance status before SCR |
|
|
|
0.311 |
| 0 |
30 |
13 |
53.28 |
|
| 1 |
26 |
9 |
109.31 |
|
| 2 |
14 |
5 |
72.0 |
|
| 3 |
5 |
3 |
14.4 |
|
|
Residual disease after SCR |
|
|
|
|
| None |
43 |
12 |
76.462 |
0.000* |
| 0.1~1 cm |
15 |
6 |
43.825 |
0.001* |
| 1~2 cm |
6 |
4 |
30.833 |
0.207 |
| >2 cm |
11 |
8 |
12.778 |
Reference |
|
Postoperative therapy after SCR |
|
|
|
|
| Chemotherapy |
48 |
22 |
40.192 |
Reference |
| Radiotherapy |
6 |
1 |
114.0 |
0.045* |
| CT+RT |
8 |
3 |
42.0 |
0.764 |
| No | 13 | 4 | 72.0 | 0.615 |
Note. a, UV, univariate; b, pelvis: including inguinal and vaginal; CT: chemotherapy; RT: radiotherapy; *P <0.05.